This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

OXFORD NANOPORE TECHNOLOGIES PLC - National German rare disease study

OXFORD NANOPORE TECHNOLOGIES PLC - National German rare disease study

12 Jun 2023

National German rare disease study Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces a research collaboration agreement with the 'Clinical Long-read Genome Initiative' (lonGER), a new national German programme developed to evaluate the clinical and research applications of comprehensive nanopore-based sequencing to advance... Read more

Oxfordshire plays a pivotal role in UK’s ambition to be a scientific superpower according to a new report by Advanced Oxford

Oxfordshire plays a pivotal role in UK’s ambition to be a scientific superpower according to a new report by Advanced Oxford

07 Jun 2023

Oxfordshire plays a pivotal role in UK’s ambition to be a scientific superpower according to a new report by Advanced Oxford Business leaders and academics alike have welcomed an insightful new report and interactive dashboard published by Advanced Oxford in conjunction with Elsevier. Oxfordshire’s Innovation Engine 2023 report assesses the growth of the region’s science and technology ecosystem over the last 10 years, the challenges ahead... Read more

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

02 Jun 2023

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting Scancell Holdings plc ("Scancell" or the "Company") Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting ModiFY trial progressing through monotherapy expansion cohorts and combination... Read more

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

17 May 2023

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics... Read more

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

15 May 2023

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More